Skip to main content
SpringerLink
Log in

Effects of Hydroxysafflor Yellow A in the Attenuation of MPTP Neurotoxicity in Mice

  • Original Paper
  • Published:
Neurochemical Research Aims and scope Submit manuscript

Abstract

Parkinson’s disease (PD) is a progressive neurodegenerative disorder whose etiology is not understood. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse model is widely used for studying PD. The present study was undertaken to investigate the effect of hydroxysafflor yellow A (HSYA) on MPTP-induced neurotoxicity in mice. Pretreatment with HSYA at a dose of 2, 8 mg/kg for a week was followed by intraperitoneal injection with MPTP (30 mg/kg) for five consecutive days. Next, the subsequent behavior, biochemical index and immunohistochemical manifestations in mice were determined. Behavioral testing showed that MPTP-treated mice exhibited motor deficits but HSYA at dose of 8 mg/kg prevented the appearance of motor abnormalities. Treatment with HSYA at dose of 8 mg/kg attenuated the reduction of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in striatum. It also showed that the activity of SOD, catalase activity and GSH levels were significantly higher, while the levels of malondialdehyde (MDA) and hydroxyl radicals was lower, in the HSYA-treated mice compared to the MPTP-treated mice. The MPTP-treated mice exhibited the loss of tyrosine hydroxylase-containing dopaminergic neurons in substantia nigra. However, HSYA-treated mice showed a protective effect. Our results indicated that HSYA possesses neuroprotective effects and is a promising anti-Parkinson’s disease drug which is worthy of further study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Hornykiewicz O, Kish SJ (1987) Biochemical pathophysiology of Parkinson’s disease. Adv Neurol 45:19–34

    CAS  PubMed  Google Scholar 

  2. Sayre LM, Perry G, Smith MA (2008) Oxidative stress and neurotoxicity. Chem Res Toxicol 21:172–188

    Article  PubMed  Google Scholar 

  3. Langston JW, Ballard P, Tetrud JW et al (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979–980

    Article  CAS  PubMed  Google Scholar 

  4. Tipton KF, Singer TP (1993) Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 61:1191–1206

    Article  CAS  PubMed  Google Scholar 

  5. Schmidt N, Ferger B (2001) Neurochemical findings in the MPTP model of Parkinson’s disease. J Neural Transm 108:1263–1282

    Article  CAS  PubMed  Google Scholar 

  6. Romano C, Price M, Bai HY et al (1993) Neuroprotectants in Honghua: glucose attenuates retinal ischemic damage. Invest Ophthalmol Vis Sci 34:72–80

    CAS  PubMed  Google Scholar 

  7. Wei X, Liu H, Sun X et al (2005) Hydroxysafflor yellow A protects rat brains against ischemia-reperfusion injury by antioxidant action. Neurosci Lett 386:58–62

    Article  CAS  PubMed  Google Scholar 

  8. Tian J, Li G, Liu Z (2008) Hydroxysafflor yellow A inhibits rat brain mitochondrial permeability transition pores by a free radical scavenging action. Pharmacology 82:121–126

    Article  CAS  PubMed  Google Scholar 

  9. Sundström E, Fredriksson A, Archer T (1990) Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson’s disease. Brain Res 528:181–188

    Article  PubMed  Google Scholar 

  10. Sedelis M, Hofele K, Auburger GW et al (2000) MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences. Behav Genet 30:171–182

    Article  CAS  PubMed  Google Scholar 

  11. Araki T, Mikami T, Tanji H et al (2001) Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse. Eur J Pharm Sci 12:231–238

    Article  CAS  PubMed  Google Scholar 

  12. McCord JM, Fridovich I (1969) Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem 244:6049–6055

    CAS  PubMed  Google Scholar 

  13. Aebi H (1984) Catalase in vitro. Methods Enzymol 105:121–126

    Article  CAS  PubMed  Google Scholar 

  14. Cohn VH, Lyle J (1966) A fluorimetric assay for glutathione. Anal Biochem 14:434–440

    Article  CAS  PubMed  Google Scholar 

  15. Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351–358

    Article  CAS  PubMed  Google Scholar 

  16. Thomas B, Muralikrishnan D, Mohanakumar KP (2000) In vivo hydroxyl radical generation in the striatum following systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Brain Res 852:221–224

    Article  CAS  PubMed  Google Scholar 

  17. Lowry OH, Rosebrough NJ, Farr AL et al (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275

    CAS  PubMed  Google Scholar 

  18. Dhanasekaran M, Albano CB, Pellet L et al (2008) Role of lipoamide dehydrogenase and metallothionein on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. Neurochem Res 33:980–984

    Article  CAS  PubMed  Google Scholar 

  19. Willis GL, Donnan GA (1987) Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice. Brain Res 402:269–274

    Article  CAS  PubMed  Google Scholar 

  20. Przedborski S, Jackson-Lewis V (1998) Mechanisms of MPTP toxicity. Mov Disord 13(Suppl 1):35–38

    PubMed  Google Scholar 

  21. Muralikrishnan D, Ebadi M, Brown-Borg HM (2002) Effect of MPTP on dopamine metabolism in Ames dwarf mice. Neurochem Res 27:457–464

    Article  CAS  PubMed  Google Scholar 

  22. Muralikrishnan D, Mohanakumar KP (1998) Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J 12:905–912

    CAS  PubMed  Google Scholar 

  23. Haavik J, Toska K (1998) Tyrosine hydroxylase and Parkinson’s disease. Mol Neurobiol 16:285–309

    Article  CAS  PubMed  Google Scholar 

  24. Hurley FM, Costello DJ, Sullivan AM (2004) Neuroprotective effects of delayed administration of growth/differentiation factor-5 in the partial lesion model of Parkinson’s disease. Exp Neurol 185:281–289

    Article  CAS  PubMed  Google Scholar 

  25. Oiwa Y, Yoshimura R, Nakai K et al (2002) Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson’s disease. Brain Res 947:271–283

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

The authors thank Prof. Lon Clark for the English language revision.

Author information

Authors and Affiliations

  1. Department of Physiology, School of Basic Medical Sciences, Jilin University, No. 2 Xinmin Street, Changchun, 130021, China

    B. Han & H. Zhao

  2. School of Pharmacy, Yantai University, Yantai, 264005, China

    B. Han

Authors
  1. B. Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. Zhao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Han, B., Zhao, H. Effects of Hydroxysafflor Yellow A in the Attenuation of MPTP Neurotoxicity in Mice. Neurochem Res 35, 107–113 (2010). https://doi.org/10.1007/s11064-009-0035-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11064-009-0035-4

Keywords

Search

Navigation